Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 3/2024

Open Access 08-03-2024 | Vulgar Psoriasis | Original Research

Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα

Authors: Julia Tittes, Jennifer Brell, Pia Fritz, Constanze Jonak, Georg Stary, Julia M. Ressler, Sarojinidevi Künig, Wolfgang Weninger, Johannes Stöckl

Published in: Dermatology and Therapy | Issue 3/2024

Login to get access

Abstract

Introduction

Targeting of the proinflammatory cytokine interleukin 17A (IL-17A) or tumor necrosis factor alpha (TNFα) with the monoclonal antibodies (mAbs) ixekizumab or adalimumab, respectively, is a successful therapy for chronic plaque psoriasis. The effects of these treatments on immune cell populations in the skin are largely unknown.

Methods

In this study, we compared the composition of cutaneous, lesional and non-lesional immune cells and blood immune cells in ixekizumab- or adalimumab-treated patients with psoriasis.

Results

Our data reveal that both treatments efficiently downregulate T cells, macrophages and different subsets of dendritic cells (DCs) in lesional skin towards levels of healthy skin. In contrast to lesional skin, non-lesional areas in patients harbor only few or no detectable DCs compared to the skin of healthy subjects. Treatment with neither ixekizumab nor adalimumab reversed this DC imbalance in non-lesional skin of psoriatic patients.

Conclusion

Our study shows that anti-IL-17A and anti-TNFα therapy rebalances the immune cell repertoire of lesional skin in psoriatic patients but fails to restore the disturbed immune cell repertoire in non-lesional skin.
Appendix
Available only for authorised users
Literature
1.
Rapp SR, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–7.PubMedCrossRef
2.
Gelfand JM, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.PubMedCrossRef
3.
Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–8.PubMedCrossRef
4.
Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1(5):442–7.PubMedCrossRef
5.
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53.PubMedPubMedCentralCrossRef
6.
Lowes MA, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A. 2005;102(52):19057–62.PubMedPubMedCentralCrossRef
7.
8.
Harrington LE, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32.PubMedCrossRef
9.
10.
Teunissen MB, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111(4):645–9.PubMedCrossRef
11.
Krueger JG, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-54.e9.PubMedPubMedCentralCrossRef
12.
Lee E, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30.PubMedPubMedCentralCrossRef
13.
Zaba LC, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129(1):79–88.PubMedCrossRef
14.
Lin AM, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490–500.PubMedCrossRef
15.
Keijsers RR, et al. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014;23(11):799–803.PubMedCrossRef
16.
Reich K, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015;24(7):529–35.PubMedPubMedCentralCrossRef
17.
Res PC, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE. 2010;5(11): e14108.PubMedPubMedCentralCrossRef
18.
Haranaka K, et al. Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor. Proc Natl Acad Sci U S A. 1986;83(11):3949–53.PubMedPubMedCentralCrossRef
19.
Schottelius AJ, et al. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol. 2004;13(4):193–222.PubMedCrossRef
20.
Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717–25.PubMedCrossRef
21.
22.
Uyemura K, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101(5):701–5.PubMedCrossRef
23.
Keijsers RR, et al. Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. Br J Dermatol. 2013;168(6):1294–302.PubMedCrossRef
24.
Mehta H, et al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with Guselkumab vs. Secukinumab. J Invest Dermatol. 2021;141(7):1707-1718.e9.PubMedCrossRef
25.
Brunner PM, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8707.PubMedPubMedCentralCrossRef
26.
Kolbinger F, et al. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139(3):923-932.e8.PubMedCrossRef
27.
Chiricozzi A, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174(1):136–45.PubMedCrossRef
28.
Wang CQF, et al. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol. 2014;134(12):2990–3.PubMedCrossRef
29.
Soler DC, et al. Increased, but functionally impaired, CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in psoriasis: a mechanism of dysregulated T cells. J Invest Dermatol. 2016;136(4):798–808.PubMedCrossRef
30.
31.
32.
33.
34.
35.
Narcisi A, et al. Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients. J Dermatol Treat. 2022;33(3):1703–6.CrossRef
36.
Simopoulou T, et al. Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. Drugs Today (Barc). 2023;59(3):135–67.PubMedCrossRef
37.
Lynde C, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting. Adv Ther. 2023;40(3):869–86.PubMedCrossRef
38.
39.
40.
41.
Chamian F, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005;102(6):2075–80.PubMedPubMedCentralCrossRef
42.
43.
Boyman O, et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004;199(5):731–6.PubMedPubMedCentralCrossRef
44.
Lande R, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–9.PubMedCrossRef
45.
Farkas A, Tonel G, Nestle FO. Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol. 2008;158(5):921–9.PubMedPubMedCentralCrossRef
46.
Dumitru CA, et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61(8):1155–67.PubMedCrossRef
47.
48.
49.
Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756–60.PubMed
50.
Perez C, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136(2):199–209.PubMedCrossRef
51.
Argyropoulos KV, et al. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides. Clin Transl Oncol. 2020;22(7):1059–66.PubMedCrossRef
52.
Loeuillard E, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020;130(10):5380–96.PubMedPubMedCentralCrossRef
53.
Janols H, et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J Leukoc Biol. 2014;96(5):685–93.PubMedCrossRef
54.
Rodriguez PC, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553–60.PubMedPubMedCentralCrossRef
55.
Denny MF, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184(6):3284–97.PubMedCrossRef
56.
57.
58.
Ilkovitch D, Ferris LK. Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules. Mol Med Rep. 2016;14(4):3935–40.PubMedPubMedCentralCrossRef
59.
Ferrer G, et al. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia. 2021;35(11):3163–75.PubMedPubMedCentralCrossRef
60.
Pember SO, et al. Density heterogeneity of neutrophilic polymorphonuclear leukocytes: gradient fractionation and relationship to chemotactic stimulation. Blood. 1983;61(6):1105–15.PubMedCrossRef
61.
Fridlender ZG, et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE. 2012;7(2): e31524.PubMedPubMedCentralCrossRef
62.
Chan JR, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–87.PubMedPubMedCentralCrossRef
63.
64.
Green L, et al. Clinical and molecular effects of interleukin-17 pathway blockade in psoriasis. J Drugs Dermatol. 2020;19(2):138–43.PubMedCrossRef
65.
Hendriks AG, et al. The effect of adalimumab on key drivers in the pathogenesis of psoriasis. Br J Dermatol. 2014;170(3):571–80.PubMedCrossRef
66.
67.
Cytlak U, et al. Differential IRF8 transcription factor requirement defines two pathways of dendritic cell development in humans. Immunity. 2020;53(2):353-370.e8.PubMedPubMedCentralCrossRef
68.
Fuentes-Duculan J, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol. 2010;130(10):2412–22.PubMedPubMedCentralCrossRef
69.
Kim J, et al. Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets. J Allergy Clin Immunol. 2021;148(5):1281–92.PubMedPubMedCentralCrossRef
70.
71.
72.
73.
Zhang B, et al. Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis. Allergy. 2023;78(2):439–53.PubMedCrossRef
74.
75.
Liu J, et al. Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8(+) T cells in autoimmunity and cancer. J Allergy Clin Immunol. 2021;147(6):2370–80.PubMedCrossRef
Metadata
Title
Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα
Authors
Julia Tittes
Jennifer Brell
Pia Fritz
Constanze Jonak
Georg Stary
Julia M. Ressler
Sarojinidevi Künig
Wolfgang Weninger
Johannes Stöckl
Publication date
08-03-2024
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 3/2024
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-024-01112-4

Other articles of this Issue 3/2024

Dermatology and Therapy 3/2024 Go to the issue

Case Report

Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib

Review

Herpes Zoster Recurrence: A Narrative Review of the Literature

Brief Report

Improvements in Plaque Psoriasis Associated with Calcipotriol/Betamethasone Aerosol Foam Treatment: A Post Hoc Analysis of Non-interventional Studies and Clinical Experience

Original Research

Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives

Original Research

Readability of Patient Electronic Materials for Atopic Dermatitis in 23 Languages: Analysis and Implications for Dermatologists

Original Research

Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits